Alonso-Curbelo, Direna
Ho, Yu-Jui
Burdziak, Cassandra
Maag, Jesper L. V.
Morris, John P. IV
Chandwani, Rohit
Chen, Hsuan-An http://orcid.org/0000-0002-8979-3670
Tsanov, Kaloyan M.
Barriga, Francisco M. http://orcid.org/0000-0002-0996-7707
Luan, Wei
Tasdemir, Nilgun
Livshits, Geulah
Azizi, Elham
Chun, Jaeyoung http://orcid.org/0000-0002-4164-0691
Wilkinson, John E.
Mazutis, Linas
Leach, Steven D. http://orcid.org/0000-0002-2689-1871
Koche, Richard http://orcid.org/0000-0002-6820-5083
Pe’er, Dana
Lowe, Scott W. http://orcid.org/0000-0002-5284-9650
Article History
Received: 29 January 2020
Accepted: 18 December 2020
First Online: 3 February 2021
Competing interests
: A patent application (PTC/US2019/041670, international filing date 12 July 2019) has been submitted based in part on results presented in this manuscript covering methods for preventing or treating <i>KRAS</i>-mutant pancreatic cancer with inhibitors of type 2 cytokine signalling. D.A.-C. and S.W.L. are listed as the inventors. S.W.L. is a founder and member of the scientific advisory board of Blueprint Medicines, Mirimus, ORIC Pharmaceuticals and Faeth Therapeutics, and is on the scientific advisory board of Constellation Pharmaceuticals and PMV Pharmaceuticals. S.D.L. is on the scientific advisory board of Nybo Therapeutics and Episteme Prognostics.